Retinal Vein Occlusion - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Retinal Vein Occlusion - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Retinal Vein Occlusion - Pipeline Review, H2 2015', provides an overview of the Retinal Vein Occlusion's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Retinal Vein Occlusion Overview 8
Therapeutics Development 9
Pipeline Products for Retinal Vein Occlusion - Overview 9
Pipeline Products for Retinal Vein Occlusion - Comparative Analysis 10
Retinal Vein Occlusion - Therapeutics under Development by Companies 11
Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes 12
Retinal Vein Occlusion - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Retinal Vein Occlusion - Products under Development by Companies 16
Retinal Vein Occlusion - Products under Investigation by Universities/Institutes 17
Retinal Vein Occlusion - Companies Involved in Therapeutics Development 18
Aerpio Therapeutics, Inc. 18
Allergan Plc 19
Avalanche Biotechnologies, Inc. 20
EyeGate Pharmaceuticals, Inc. 21
F. Hoffmann-La Roche Ltd. 22
Gene Signal International SA 23
Kala Pharmaceuticals, Inc. 24
Mabion SA 25
NicOx S.A. 26
Ohr Pharmaceutical Inc. 27
pSivida Corp. 28
ThromboGenics NV 29
Retinal Vein Occlusion - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
aganirsen - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AKB-9778 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AVA-101 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
beclomethasone dipropionate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
dexamethasone acetate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
fluocinolone acetonide SR - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
loteprednol etabonate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
NCX-422 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NCX-434 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ocriplasmin (recombinant) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Peptides to Inhibit Phosphatidylserine for Central Retinal Vein Occlusion - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ranibizumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ranibizumab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Recombinant Protein for Central Retinal Vein Occlusion - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
squalamine lactate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Retinal Vein Occlusion - Recent Pipeline Updates 66
Retinal Vein Occlusion - Discontinued Products 91
Retinal Vein Occlusion - Product Development Milestones 92
Featured News & Press Releases 92
Nov 04, 2015: Alimera Sciences announces late breaking presentation of new ILUVIEN Analysis During Retina Subspecialty day at AAO annual meeting 2015 92
Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN 92
Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 93
Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 94
Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 95
Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 96
Sep 27, 2013: New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications 96
Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 98
May 08, 2013: Novartis Reports New Data On Lucentis At Association For Research In Vision And Ophthalmology Annual Meeting 98
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2015 9
Number of Products under Development for Retinal Vein Occlusion - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H2 2015 18
Retinal Vein Occlusion - Pipeline by Allergan Plc, H2 2015 19
Retinal Vein Occlusion - Pipeline by Avalanche Biotechnologies, Inc., H2 2015 20
Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 21
Retinal Vein Occlusion - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 22
Retinal Vein Occlusion - Pipeline by Gene Signal International SA, H2 2015 23
Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H2 2015 24
Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2015 25
Retinal Vein Occlusion - Pipeline by NicOx S.A., H2 2015 26
Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H2 2015 27
Retinal Vein Occlusion - Pipeline by pSivida Corp., H2 2015 28
Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2015 29
Assessment by Monotherapy Products, H2 2015 30
Number of Products by Stage and Target, H2 2015 32
Number of Products by Stage and Mechanism of Action, H2 2015 34
Number of Products by Stage and Route of Administration, H2 2015 36
Number of Products by Stage and Molecule Type, H2 2015 38
Retinal Vein Occlusion Therapeutics - Recent Pipeline Updates, H2 2015 66
Retinal Vein Occlusion - Discontinued Products, H2 2015 91